Anitbody biotech Alder BioPharmaceuticals files for a $115 million IPO
Alder BioPharmaceuticals, a biotech developing antibodies to treat migraines and arthritis, filed on Wednesday with the SEC to raise up to $115 million in an initial public offering. The Bothell, WA-based company, which was founded in 2002 and booked $19 million in collaboration and licensing revenue for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol ALDR. Alder BioPharmaceuticals initially filed confidentially on February 10, 2014. Credit Suisse and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.